Vepdegestrant brings PROTAC technology into breast cancer, validating targeted protein degradation in ESR1-mutant ER+/HER2− ...

"The second quarter marked continued momentum across our zovegalisib program, with advances in our frontline breast cancer development strategy and the presentation of initial clinical data at ISSVA ...

MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom Edinburgh Cancer Research, CRUK Scotland Centre, Institute of Genetics and Cancer, The ...

Treatment of metastatic, castration-resistant prostate cancer (mCRPC) remains clinically challenging due to tumor heterogeneity and resistance to standard microtubule-targeting agents, such as ...

Triplet gedatolisib/fulvestrant/palbociclib achieved the primary endpoint, significantly improving PFS versus alpelisib/fulvestrant in PIK3CA-mutant HR+/HER2− ...

Breast cancer is one of the most common malignancies worldwide, and mutations in the PI3K/AKT/mTOR (PAM) signaling pathway are prevalent in its development. Among these, PIK3CA mutations play a ...

ABSTRACT: Background: Gynecologic clear cell carcinoma (CCC) represents a rare and biologically distinct subgroup of gynecologic malignancies arising predominantly from the ovary and endometrium, and ...

Mutations in the PIK3CA gene that lead to elevated production of the PI3Ka protein are among the most frequent alterations found in cancer, including in approximately 40% of hormone receptor–positive ...

After a Consumer Reports investigation revealed that some popular protein powders and shakes contained troubling levels of lead, many readers wrote in with a simple question: What does this mean for ...